The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...

When it comes to daylight savings, one hour might not seem like a major difference in the grand scheme of things. However, ...

“Children, how hard it is to enter the Kingdom of God! It is easier for a camel to pass through the eye of a needle. than for one who is rich to enter the Kingdom of God.” It could be one of ...

When it comes to tackling dark circles, fine lines and puffiness, the best eye creams are designed with delicate skin in mind. Their formulas are specifically created for the under-eye area ...

Have you ever had an episode where one of your eyes has been twitching uncontrollably for a few days? An eye twitch, while annoying, is usually nothing serious. A twitching eye is a creepy sensation, ...

Eye lymphoma, also called ocular lymphoma, is a type of eye cancer. It is the most common type of malignant eye tumor. The condition may cause eye redness or decreased vision, and it can advance to ...

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not ...

Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price ...

Games Car rental Your eyes are said to be the window to your soul — but they may also be a window to your health. Your eye color may signal a predisposition to certain medical conditions, such as skin ...

Originally developed by Regeneron (Nasdaq: REGN) and Bayer (BAYN: DE), Eylea, a widely-used biologic for the treatment of eye disorders ... All the news that moves the needle in pharma and biotech ...

agreed to review their AVTO6 treatment for eye disorders. The treatment could compete with Regeneron Pharmaceuticals’ (REGN) Eylea, which is widely used to treat diseases such as neovascular ...

blockbuster eye disease therapy, Eylea. A biologic named AVT06, Teva (NYSE:TEVA), and Alvotech’s (NASDAQ:ALVO) biosimilar, is backed by positive data from a clinical trial for patients with ...